Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy
Source abstract
Abstract
With the capability of specific silencing of target gene expression, RNA interference (RNAi) technology is emerging as a promising therapeutic modality for the treatment of cancer and other diseases. One key challenge for the clinical applications of RNAi is the safe and effective delivery of RNAi agents such as small interfering RNA (siRNA) to a particular nonliver diseased tissue (e.g., tumor) and cell type with sufficient cytosolic transport. In this work, we proposed a multifunctional envelope-type nanoparticle (NP) platform for prostate cancer (PCa)-specific in vivo siRNA delivery. A library of oligoarginine-functionalized and sharp pH-responsive polymers was synthesized and used for self-assembly with siRNA into NPs with the features of long blood circulation and pH-triggered oligoarginine-mediated endosomal membrane penetration. By further modification with ACUPA, a small molecular ligand specifically recognizing prostate-specific membrane antigen (PSMA) receptor, this envelope-type nanoplatform with multifunctional properties can efficiently target PSMA-expressing PCa cells and silence target gene expression. Systemic delivery of the siRNA NPs can efficiently silence the expression of prohibitin 1 (PHB1), which is upregulated in PCa and other cancers, and significantly inhibit PCa tumor growth. These results suggest that this multifunctional envelope-type nanoplatform could become an effective tool for PCa-specific therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
King Abdulaziz University, Jeddah 21589, Saudi Arabia
Funding
National Cancer Institute · National Heart, Lung, and Blood Institute · Movember Foundation · National Research Foundation of Korea · National Institute of Biomedical Imaging and Bioengineering · Prostate Cancer Foundation
References (52)
Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. 10.1001/jama.293.17.209510.1001/jama.293.17.2095 ↗
3. 10.1016/S1470-2045(03)01035-010.1016/S1470-2045(03)01035-0 ↗
4. 10.1200/JCO.2005.02.975110.1200/JCO.2005.02.9751 ↗
5. 10.1073/pnas.060175510310.1073/pnas.0601755103 ↗
6. 10.1177/175883401244968510.1177/1758834012449685 ↗
7. 10.1038/nmat376510.1038/nmat3765 ↗
8. 10.1038/nrg376310.1038/nrg3763 ↗
9. 10.1038/nrd274210.1038/nrd2742 ↗
10. 10.1002/anie.20150603010.1002/anie.201506030 ↗
11. 10.1016/j.addr.2009.03.00310.1016/j.addr.2009.03.003 ↗
12. 10.1016/j.addr.2009.04.00110.1016/j.addr.2009.04.001 ↗
13. 10.1002/anie.20110155410.1002/anie.201101554 ↗
14. 10.1038/nrd468510.1038/nrd4685 ↗
15. 10.1038/nature0468810.1038/nature04688 ↗
16. 10.1038/nature0895610.1038/nature08956 ↗
17. 10.1158/2159-8290.CD-12-042910.1158/2159-8290.CD-12-0429 ↗
18. 10.1073/pnas.141139311110.1073/pnas.1411393111 ↗
19. Vaupel P. · 2013 · 765 · 29910.1007/978-1-4614-4989-8_42 ↗
20. 10.3109/0036559790918116810.3109/00365597909181168 ↗
21. Israeli R. S. · Cancer Res. · 1993 · 53 · 227
22. 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T ↗
23. 10.1073/pnas.080915410510.1073/pnas.0809154105 ↗
24. 10.1002/anie.20090267210.1002/anie.200902672 ↗
25. 10.1021/ar200151m10.1021/ar200151m ↗
26. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
27. 10.2217/nnm.12.13410.2217/nnm.12.134 ↗
28. 10.1126/scitranslmed.300365110.1126/scitranslmed.3003651 ↗
29. 10.1021/nn203503h10.1021/nn203503h ↗
30. 10.1002/anie.20110088410.1002/anie.201100884 ↗
31. 10.1002/anie.20160127310.1002/anie.201601273 ↗
32. 10.1021/am404680n10.1021/am404680n ↗
33. 10.1016/j.biomaterials.2010.10.04710.1016/j.biomaterials.2010.10.047 ↗
34. 10.1002/anie.20070273210.1002/anie.200702732 ↗
35. 10.1016/j.chembiol.2013.02.00610.1016/j.chembiol.2013.02.006 ↗
36. 10.1016/j.bbamcr.2011.01.03310.1016/j.bbamcr.2011.01.033 ↗
37. 10.1016/j.humpath.2012.12.01010.1016/j.humpath.2012.12.010 ↗
38. 10.1002/ijc.2335110.1002/ijc.23351 ↗
39. 10.1016/j.molmed.2005.02.00410.1016/j.molmed.2005.02.004 ↗
40. 10.1073/pnas.091064910710.1073/pnas.0910649107 ↗
41. 10.1073/pnas.150562911210.1073/pnas.1505629112 ↗
42. 10.1038/nmat381910.1038/nmat3819 ↗
43. 10.1038/nm.185410.1038/nm.1854 ↗
44. 10.1034/j.1399-3011.2000.00723.x10.1034/j.1399-3011.2000.00723.x ↗
45. 10.1074/jbc.M11001720010.1074/jbc.M110017200 ↗
46. 10.1007/s00018-006-6170-z10.1007/s00018-006-6170-z ↗
47. 10.1126/scitranslmed.300377810.1126/scitranslmed.3003778 ↗
48. 10.1038/mtna.2013.510.1038/mtna.2013.5 ↗
49. 10.1074/jbc.M30517120010.1074/jbc.M305171200 ↗
50. 10.1007/s10142-011-0210-y10.1007/s10142-011-0210-y ↗
51. 10.1007/s10571-010-9608-710.1007/s10571-010-9608-7 ↗
52. 10.1038/nprot.2011.41810.1038/nprot.2011.418 ↗